Arrevus announces receipt of NIH grant to support research using ARV-1502 to combat antibiotic-resistant wound infections

RALEIGH, N.C., March 27, 2018 /PRNewswire/ -- Arrevus Inc. (www.arrevus.com), a biotechnology company focused on developing chaperone protein inhibitors for infectious diseases, today announced receipt of a $300,000 grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), to further research using one of its products, ARV-1502, for the treatment of antibiotic-resistant wound infections.

"We appreciate the NIH's recognition of our novel chaperone protein inhibitor research. With this award, as well as with our recent closing of our Series A funding, Arrevus can accelerate the development of a new class of antimicrobials against antibiotic-resistant infections," said Carl N. Kraus, M.D., President and CEO of Arrevus.

In the United States, over $50 billion are spent annually treating chronic wound infections, many of which are the result of antimicrobial-resistant bacteria.  Wound infections impact both civilian and military populations.  For the military, wound infections are a critical risk of combat-related trauma, which is a significant hazard to long-term survival and return to normal function.  

"The development of novel strategies to address antimicrobial resistance in wound infections is critical," said Robert D. Galiano, M.D., Associate Professor of Surgery at Northwestern University, and collaborator on the grant.

Wounds spread various types of antibiotic-resistant bacteria, one of which is methicillin-resistant Staphylococcus aureus (MRSA). Preliminary data in a mouse model using MRSA showed that with a single dose of ARV-1502:

• wound healing is accelerated
• bacterial burden is decreased
• immune response is stimulated

These data support the continued development of ARV-1502 against antibiotic-resistant infections for which novel approaches are needed.

About Arrevus
Arrevus is a biotechnology company whose mission is to eliminate the threat of antibiotic resistance and improve treatment outcomes for serious infectious diseases.  Arrevus is applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs).  Arrevus is headquartered in Raleigh, NC. For more information about Arrevus Inc., visit www.arrevus.com or email [email protected].

SOURCE Arrevus

Related Links

http://www.arrevus.com